



Vitamin D Status and its therapeutic role in Children with Idiopathic Nephrotic Syndrome

Thesis

Submitted for the Partial Fulfillment of M.D. Degree in Pediatrics

By

Dina Ebrahim Darweish Sallam

M.B. B.Ch. 2008 – MSc in Pediatrics 2013

Assistant lecturer of Pediatrics

Faculty of Medicine, Ain-Shams University

Under supervision of

Dr. Ihab Zaki El-Hakim

Professor of Pediatrics

Faculty of medicine, Ain-Shams University

Dr. Nermine Hussein Amr

Professor of Pediatrics

Faculty of Medicine, Ain-Shams University

Dr. Dalia Helmy El-Ghoneimy

Assistant Professor of Pediatrics

Faculty of Medicine, Ain-Shams University

Dr. Dina Ahmed Soliman

Assistant Professor of Clinical Pathology

Faculty of Medicine, Ain-Shams University

Dr. Ahmed Hussein Hassan

Lecturer of Pediatrics

Faculty of Medicine, Ain-Shams University

Faculty of Medicine

Ain-Shams University

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

First, thanks are all due to Allah for Blessing this work until it has reached its end.

*My profound thanks and deep appreciation to **Prof. Dr. Ihab Zaki El-Hakim**, Professor of Pediatrics, Faculty of Medicine- Ain Shams University for his great support and advice, his valuable remarks that gave me the confidence and encouragement to fulfill this work.*

*I am deeply grateful to **Dr. Nermine Hussein Amr** Professor of Pediatrics, Faculty of Medicine-Ain Shams University for adding a lot to this work through her experience and for her keen supervision.*

*I am thankful to **Dr. Dalia Helmy El-Ghoneimy** Assistant Professor of Pediatrics, Faculty of Medicine-Ain Shams University for her valuable supervision, co-operation and direction that extended throughout this work.*

*Special thanks to **Dr. Dina Ahmed Soliman** Assistant Professor of Clinical Pathology, Faculty of Medicine-Ain Shams University for her kind help and co-operation and direction that extended throughout this work.*

*I would like to direct my special thanks to **Dr. Ahmed Hussein Hassan** Lecturer of Pediatrics, Faculty of Medicine-Ain Shams University, for his invaluable help, fruitful advice, continuous support offered to me and guidance step by step till this thesis finished.*

I'd like to thank my dear patients who agreed to participate in this study.

Last but not least, I dedicate this work to my family, without its sincere emotional support, pushing me forward; this work would not have ever been completed.

This work was supported by Ain Shams Faculty of Medicine Grants Office.

Dina Ebrahim Darweish Sallam

List of Contents

	page
List of Abbreviations.....	II
List of Tables.....	IV
List of Figures	VII
Abstract	1
Introduction	3
Aim of the work	6
Review of literature	7
Nephrotic syndrome	7
Vitamin D.....	34
Interferon gamma (IFN- γ)	46
Nephrotic syndrome, interferon gamma (IFN- γ) and vitamin D cross-talks	52
Subjects and Methods.....	62
Results.....	74
Discussion	100
Conclusion.....	111
Recommendations	112
Summary	113
References	117
Arabic Summary	-

List of Abbreviations

Abb.	Full Term
1, 25 (OH)₂ D₃	: 1, 25-Dihydroxyvitamin D ₃
25(OH) D₃	: 25-hydroxyvitamin D ₃
ACEIs	: Angiotensin converting enzyme inhibitors
Ag	: Antigen
ALP	: Alkaline phosphatase
APCs	: Antigen presenting cells
ARBs	: Angiotensin receptor blockers
CBC	: Complete blood count
CKD	: Chronic kidney disease
CKD5	: Chronic kidney disease stage 5
CNI s	: Calcineurin inhibitors
Cs A	: Cyclosporine
CXCL16	: C-X-C motif chemokine ligand 16
DCs	: Dendritic cells.
DMP	: Diffuse mesangial proliferation
ELISAs	: Enzyme-linked immunosorbent assays
FOXP3	: Forkhead box protein 3
FSGS	: Focal segmental glomerulosclerosis
GM-CSF	: Granulocyte-macrophage colony-stimulating factor
KDIGO	: Kidney Disease, Improving Global Outcomes
HMCs	: Human mesangial cells
HMG CoA	: Hydroxymethylglutaryl CoA
IFN-γ	: Interferon- gamma
IL-1	: Interleukin-1
IL-13Rα2	: Interleukin 13 receptor alpha 2
IL-4Rα	: Interleukin 4 receptor alpha
INOS	: Inducible nitric oxide synthase
INS	: Idiopathic nephrotic syndrome
IOM	: Institute of Medicine
IPEX	: Immune dysregulation, polyendocrinopathy, enteropathy and X-linked syndrome
IPNA	: International Pediatric Nephrology Association
IU	: International unit
JC virus	: John Cunningham virus
MCNS	: Minimal change nephrotic syndrome
MHC II	: Major histocompatibility
MMF	: Mycophenolate Mofetil

Abb.	Full Term
MRNA	: Messenger RNA
Mϕ	: Macrophage
NS	: Nephrotic syndrome
OxLDL	: Oxidized low density lipoprotein
PMNs	: Polymorphonuclear
PTH	: Parathyroid hormone
RANKL	: Receptor activator of nuclear factor-kB ligand
RDA	: Recommended daily allowance
RRT	: Renal replacement therapy
RTX	: Rituximab
SCTLA-4	: Soluble cytotoxic T-lymphocyte antigen 4
SDNS	: Steroid-dependant nephrotic syndrome
SRNS	: Steroid-resistant nephrotic syndrome
SSNS	: Steroid-sensitive nephrotic syndrome
TCR	: T cell receptor
TG	: Triglyceride
TGF β	: Tissue growth factor beta
TLR	: Toll-like-receptor
TNF	: Tumor necrosis factor
Treg	: T regulatory cell
UV	: Ultraviolet
VDBP	: Vitamin D binding protein
VDR	: Vitamin D receptor

List of Tables

Table no.	Title	page
i	Definitions of nephrotic syndrome in children.....	7
ii	Causes of secondary nephrotic syndrome	10
iii	Etiopathological role of cytokines in MCNS	16
iv	Infections in nephrotic syndrome	20
v	Thrombosis in nephrotic syndrome	22
vi	Recommended daily allowance of vitamin D	41
1	Characteristics of the studied patients in both groups at enrollment of the study and comparison between them.....	74
2	Descriptive and comparative serum level of both forms of vitamin D and IFN- γ in both groups at initial diagnosis.....	76
3	Descriptive and comparative kidney function tests, total proteins and serum albumin, corrected total calcium, phosphorous and alkaline phosphatase in both groups at initial diagnosis.....	76
4	Descriptive and comparative kidney function test, complete blood count, lipid profile and urinary protein creatinine ration in both groups at initial diagnosis.....	77
5	Comparison between the studied groups as regards vitamin D status (25 (OH) D ₃) at the diagnosis	79
6	Correlation of 1, 25 (OH) ₂ D ₃ at initial diagnosis with other variables in both studied groups	79
7	Correlation of 25 (OH) D ₃ at initial diagnosis with other laboratory investigations in both studied groups.....	80
8	Correlation of IFN- γ at initial diagnosis with the age of the patients and other laboratory investigations in both groups.....	81
9	Descriptive and comparative laboratory investigations and day of early remission in both groups at early remission	82

Table no.	Title	page
10	Variations of serum levels of active vitamin D (1, 25 (OH) ₂ D ₃), 25 (OH) D ₃ and serum albumin between initial diagnosis and early remission in group 1.....	83
11	Variations of serum levels of active form of vitamin D (1, 25 (OH) ₂ D ₃), 25 (OH) D ₃ and serum albumin between initial diagnosis and early remission in group 2....	83
12	Correlation of 1, 25 (OH) ₂ D ₃ at early remission with other variables in both group 1 & 2	84
13	Correlation of number of days to early remission with both forms of vitamin D, serum albumin and cumulative dose of prednisolone in both studied groups	85
14	Descriptive and comparative both forms of vitamin D, IFN-γ, corrected total calcium, phosphorous, alkaline phosphatase, total proteins, serum albumin and kidney function tests in both groups at full remission	86
15	Descriptive and comparative complete blood count, lipid profile and cumulative dose of prednisolone in both groups at full remission	87
16	Comparison between both studied groups as regards vitamin D status (25 (OH) D ₃) at full remission	89
17	Variations of serum levels of active vitamin D (1, 25 (OH) ₂ D ₃), 25 (OH) D ₃ and serum albumin between initial diagnosis and early remission in group 1.....	90
18	Variations of serum levels of active vitamin D (1, 25 (OH) ₂ D ₃), 25 (OH) D ₃ and serum albumin between initial diagnosis and early remission in group 2.....	90
19	Variations of serum levels of active vitamin D (1, 25 (OH) ₂ D ₃), 25 (OH) D ₃ and serum albumin between early and full remission in group 1.....	91
20	Variations of serum levels of active vitamin D (1, 25 (OH) ₂ D ₃), 25 (OH) D ₃ and serum albumin between early and full remission in group 2.....	91
21	Variations of serum levels of active vitamin D (1, 25 (OH) ₂ D ₃) and 25 (OH) D ₃ between initial diagnosis and full remission in group 1.....	92

Table no.	Title	page
22	Variations of serum levels of active vitamin D (1, 25 (OH) ₂ D ₃) and 25 (OH) D ₃ between initial diagnosis and full remission in group 2.....	92
23	Variations of IFN- γ , lipid profile, differential leucocytic counts and serum albumin levels from initial diagnosis and full remission in group 1	94
24	Variations of IFN- γ , lipid profile, differential leucocytic counts and serum albumin levels from initial diagnosis and full remission in group 2	95
25	Correlation of 1, 25 (OH) ₂ D ₃ at full remission with other variables of both group	96
26	Correlation of 25 (OH) D ₃ at full remission with other variables of both groups	97
27	Correlation of IFN- γ at full remission with other variables of both groups	98
28	Regression table for determinants of day of early remission	99

List of Figures

Figure no.	Title	page
i	Electron microscopy showing the normal aspect of podocytes with their foot processes on the left and their effacement in minimal change disease on the right	9
ii	The two hit theory in podocyte immune disorder	12
iii	T cells differentiation	13
iv	Proposed algorithm for the treatment of idiopathic SDNS.....	24
v	Proposed algorithm for the treatment of idiopathic SRNS.....	25
vi	Synthesis and action of vitamin D.....	35
vii	Vitamin D plasma levels and its physiology.....	37
viii	Monomer form of IFN- γ	48
ix	Dimmer form of IFN- γ	48
x	The immune effects of vitamin D	60
xi	Vitamin D cross-talk with Th 1, Th 2 and antigen presenting cells.....	61
1	Correlation between day of early remission and serum level of 25 (OH) D ₃ in group 2.....	85
2	Variations of serum level 1, 25 (OH) ₂ D ₃ between initial diagnosis, early remission and full remission in both groups	93
3	Variations of serum level 25 (OH) D ₃ between initial diagnosis, early remission and full remission in both groups	93
4	Correlation between 1, 25 (OH) ₂ D ₃ and total leucocytic count at full remission in group 2	96
5	Correlation between IFN- γ and total leucocytic count at full remission in group 1	98